FDA Approves Eli Lilly’s Jaypirca for Relapsed Mantle Cell Lymphoma
Eli Lilly has received FDA approval for Jaypirca, a non-covalent BTK inhibitor, in relapsed mantle cell lymphoma (MCL) patients who have relapsed after treatment with other drugs in the class. Adult MCL patients who have previously received at least two lines of systemic therapy, including a covalent BTK inhibitor, are eligible for accelerated approval.
Jaypirca (pirtobrutinib) was developed specifically for patients who develop resistance mutations to currently available BTK inhibitors for MCL, such as AbbVie/Johnson & Johnson's Imbruvica (ibrutinib), AstraZeneca's Calquence (acalabrutinib)...
